A examine meant to function a tie-breaker between two main trials of a coronary heart clip made by Abbott could find yourself stimulating extra debate amongst cardiologists.
Outcomes of the RESHAPE-HF 2 trial, offered on the European Society of Cardiology assembly and printed within the New England Journal of Drugs on Saturday, confirmed that the clip improved well being standing and lowered hospitalizations on account of coronary heart failure, however didn’t scale back the variety of deaths.
The system is supposed to deal with sufferers with mitral regurgitation, a situation the place blood leaks backward into the left coronary heart chamber. It will probably trigger uncomfortable signs like fatigue and in extreme instances, can result in coronary heart failure. Abbott’s system, known as the MitraClip, works by clipping the mitral valve’s leaflets collectively to forestall blood leakage.
This text is unique to STAT+ subscribers
Unlock this text — and get extra evaluation of the applied sciences disrupting well being care — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
